Remove 2024 Remove Heart Dysfunction Remove Kidney Disease
article thumbnail

SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

As evidence has mounted pointing to their benefits in reducing heart failure and other forms of heart disease, researchers have sought to determine whether these drugs could help to prevent heart failure even in people without diabetes or chronic kidney disease. About 32% had Type 2 diabetes. “In

article thumbnail

EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24, 24, being held in Atlanta, GA.